Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes

Evidence has been accumulating that shows that insulin-dependent diabetes is subject to immunoregulation. To determine whether cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is involved, we injected anti–CTLA-4 mAb into a TCR transgenic model of diabetes at different stages of disease. When injected into young mice, months before they would normally become diabetic, anti–CTLA-4 induced diabetes rapidly and essentially universally; this was not the result of a global activation of T lymphocytes, but did reflect a much more aggressive T cell infiltrate in the pancreatic islets. These effects were only observed if anti–CTLA-4 was injected during a narrow time window, before the initiation of insulitis. Thus, engagement of CTLA-4 at the time when potentially diabetogenic T cells are first activated is a pivotal event; if engagement is permitted, invasion of the islets occurs, but remains quite innocuous for months, if not, insulitis is much more aggressive, and diabetes quickly ensues.

[1]  M. Mattéi,et al.  Genetic control of diabetes progression. , 1997, Immunity.

[2]  J. Allison,et al.  Co-stimulation in T cell responses. , 1997, Current opinion in immunology.

[3]  Yan Wu,et al.  CTLA-4–B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion , 1997, The Journal of experimental medicine.

[4]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[5]  J. Bluestone Is CTLA-4 a master switch for peripheral T cell tolerance? , 1997, Journal of immunology.

[6]  A. Sharpe,et al.  Costimulation and autoimmunity. , 1996, Current opinion in immunology.

[7]  M. Allen,et al.  Human Influence on the Atmospheric Vertical Temperature Structure: Detection and Observations , 1996, Science.

[8]  J. Allison,et al.  The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses , 1996, Immunological reviews.

[9]  E. Fuchs,et al.  CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. , 1996, Immunity.

[10]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[11]  Nitin J. Karandikar,et al.  CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.

[12]  J. Todd,et al.  The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. , 1996, Human molecular genetics.

[13]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[14]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[15]  T. Mak,et al.  Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4 , 1996, Science.

[16]  R. Tisch,et al.  Insulin-Dependent Diabetes Mellitus , 1996, Cell.

[17]  T. Sullivan,et al.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. , 1996, International immunology.

[18]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[19]  C. Benoist,et al.  Checkpoints in the progression of autoimmune disease: lessons from diabetes models. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[21]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[22]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[23]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[24]  C Benoist,et al.  T helper cell subsets in insulin-dependent diabetes. , 1995, Science.

[25]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[26]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[27]  J. Bach,et al.  Insulin-dependent diabetes mellitus as an autoimmune disease. , 1994, Endocrine reviews.

[28]  C. Benoist,et al.  Following a diabetogenic T cell from genesis through pathogenesis , 1993, Cell.

[29]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[30]  J. Allison,et al.  Identification and distribution of the costimulatory receptor CD28 in the mouse. , 1992, Journal of immunology.

[31]  D. Gray,et al.  Mice lacking MHC class II molecules , 1991, Cell.

[32]  K. Haskins,et al.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. , 1990, Science.

[33]  C. Benoist,et al.  MHC-linked protection from diabetes dissociated from clonal deletion of T cells. , 1990, Science.